Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020–2027

細胞治療の世界市場2020–2027:機会分析・産業予測

◆タイトル:Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020–2027
◆商品コード:ALD20NV72
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年9月
◆ページ数:241
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:ライフサイエンス
◆販売価格オプション(消費税別)
Single UserUSD5,769 ⇒換算¥599,976見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、細胞治療の世界市場を調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、細胞別(幹細胞、非幹細胞)分析、治療タイプ別(自家移植、同種移植)分析、治療領域別(悪性腫瘍、筋骨格障害、自己免疫疾患、皮膚病、その他)分析、エンドユーザー別(病院・クリニック、学術・研究施設)分析、地域別分析、企業情報と今後の方向性を明らかに致します。
・イントロダクション
・研究方法
・エグゼクティブサマリー
・市場概要
・細胞治療の世界市場規模:細胞別(幹細胞、非幹細胞)
・細胞治療の世界市場規模:治療タイプ別(自家移植、同種移植)
・細胞治療の世界市場規模:治療領域別(悪性腫瘍、筋骨格障害、自己免疫疾患、皮膚病、その他)
・細胞治療の世界市場規模:エンドユーザー別(病院・クリニック、学術・研究施設)
・細胞治療の世界市場規模:地域別
・企業情報

The global cell therapy market accounted for $7,754.89 million in 2019, and is expected to reach $48,115.40 million by 2027, registering a CAGR of 25.6% from 2020 to 2027.
Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient’s body to replace diseased or missing ones.

This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.
Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy.

In addition, growth in aging patient population, rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market.
Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future.

The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others.
The global cell therapy market is categorized on the basis of therapy type, therapeutic, cell type, end user and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutic area, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. On the basis of cell type, it is segregated into stem cell therapy and non-stem cell type. On the basis of end user, it is segregated into hospital & clinics and academic & research institutes. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global cell therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.
• Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps in understanding the forms and types of cell therapy used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Cell Type
• Stem Cell
o Bone Marrow
o Blood
o Umbilical Cord-Derived
o Adipose-Derived Stem Cell
o Others
• Non-stem Cell

By Therapeutic Area
• Malignancies
• Musculoskeletal Disorders
• Autoimmune Disorders
• Dermatology
• Others

By Therapy Type
• Autologous
• Allogeneic

By End User
• Hospitals & Clinics
• Academic & Research Institutes

By Region
North America
• U.S.
• Canada
• Mexico
Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific
• Japan
• China
• India
• Australia
• Rest of Asia-Pacific
LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• ALLOSOURCE
• CELLS FOR CELLS
• HOLOSTEM TERAPIE AVANZATE SRL
• JCR PHARMACEUTICALS CO., LTD
• KOLON TISSUEGENE, INC
• MEDIPOST CO., LTD.
• MESOBLAST LTD.
• NUVASIVE, INC.
• OSIRIS THERAPEUTICS, INC.
• STEMEDICA CELL TECHNOLOGIES, INC.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top player positioning
3.2.2.Top investment pockets
3.2.3.Top winning strategies

3.3.Porter’s five forces analysis
3.4.Impact Analysis

3.4.1.Drivers

3.4.1.1.Technological advancements in the field of cell therapy
3.4.1.2.Rise in number of cell therapy clinical studies
3.4.1.3.Rise in adoption of regenerative medicine

3.4.2.Restraint

3.4.2.1.Developing stage and pricing

3.4.3.Opportunity

3.4.3.1.High growth potential in emerging markets

3.5.Impact of COVID-19 on cell therapy market

CHAPTER 4:CELL THERAPY MARKET, BY CELL TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Stem cell

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market size and forecast, by type

4.2.3.1.Bone marrow, market size and forecast
4.2.3.2.Blood, market size and forecast
4.2.3.3.Umbilical cord-derived, market size and forecast
4.2.3.4.Adipose-derived stem cell, market size and forecast
4.2.3.5.Others (placenta, and nonspecific cells), market size and forecast

4.3.Non-stem cell

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region

CHAPTER 5:CELL THERAPY MARKET, BY THERAPY TYPE

5.1.Overview

5.1.1.Market size and forecast

5.2.Autologous

5.2.1.Key market trends and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Allogeneic

5.3.1.Key market trends and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

CHAPTER 6:CELL THERAPY MARKET, BY THERAPEUTIC AREA

6.1.Overview

6.1.1.Market size and forecast

6.2.Malignancies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Musculoskeletal disorders

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Autoimmune disorders

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

6.5.Dermatology

6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country

6.6.Others

6.6.1.Market size and forecast, by region
6.6.2.Market analysis, by country

CHAPTER 7:CELL THERAPY MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospitals & clinics

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market analysis, by country

7.3.Academic & Research Institutes

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market analysis, by country

CHAPTER 8:CELL THERAPY MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends and opportunities
8.2.2.Market size and forecast
8.2.3.Market size and forecast, by cell type
8.2.4.Market size and forecast, by therapy type
8.2.5.Market size and forecast, by therapeutic area
8.2.6.Market size and forecast, by end user

8.2.6.1.U.S. market size and forecast

8.2.6.1.1.Market size and forecast, by cell type
8.2.6.1.2.Market size and forecast, by therapy type
8.2.6.1.3.Market size and forecast, by therapeutic area
8.2.6.1.4.Market size and forecast, by end user

8.2.6.2.Canada market size and forecast

8.2.6.2.1.Market size and forecast, by cell type
8.2.6.2.2.Market size and forecast, by therapy type
8.2.6.2.3.Market size and forecast, by therapeutic area
8.2.6.2.4.Market size and forecast, by end user

8.2.6.3.Mexico market size and forecast

8.2.6.3.1.Market size and forecast, by cell type
8.2.6.3.2.Market size and forecast, by therapy type
8.2.6.3.3.Market size and forecast, by therapeutic area
8.2.6.3.4.Market size and forecast, by end user

8.3.Europe

8.3.1.Key market trends and opportunities
8.3.2.Market size and forecast
8.3.3.Market size and forecast, by cell type
8.3.4.Market size and forecast, by therapy type
8.3.5.Market size and forecast, by therapeutic area
8.3.6.Market size and forecast, by end user

8.3.6.1.UK market size and forecast

8.3.6.1.1.Market size and forecast, by cell type
8.3.6.1.2.Market size and forecast, by therapy type
8.3.6.1.3.Market size and forecast, by therapeutic area
8.3.6.1.4.Market size and forecast, by end user

8.3.6.2.Germany market size and forecast

8.3.6.2.1.Market size and forecast, by cell type
8.3.6.2.2.Market size and forecast, by therapy type
8.3.6.2.3.Market size and forecast, by therapeutic area
8.3.6.2.4.Market size and forecast, by end user

8.3.6.3.France market size and forecast

8.3.6.3.1.Market size and forecast, by cell type
8.3.6.3.2.Market size and forecast, by therapy type
8.3.6.3.3.Market size and forecast, by therapeutic area
8.3.6.3.4.Market size and forecast, by end user

8.3.6.4.Spain market size and forecast

8.3.6.4.1.Market size and forecast, by cell type
8.3.6.4.2.Market size and forecast, by therapy type
8.3.6.4.3.Market size and forecast, by therapeutic area
8.3.6.4.4.Market size and forecast, by end user

8.3.6.5.Italy market size and forecast

8.3.6.5.1.Market size and forecast, by cell type
8.3.6.5.2.Market size and forecast, by therapy type
8.3.6.5.3.Market size and forecast, by therapeutic area
8.3.6.5.4.Market size and forecast, by end user

8.3.6.6.Rest of Europe market size and forecast

8.3.6.6.1.Market size and forecast, by cell type
8.3.6.6.2.Market size and forecast, by therapy type
8.3.6.6.3.Market size and forecast, by therapeutic area
8.3.6.6.4.Market size and forecast, by end user

8.4.Asia-Pacific

8.4.1.Key market trends and opportunities
8.4.2.Market size and forecast
8.4.3.Market size and forecast, by cell type
8.4.4.Market size and forecast, by therapy type
8.4.5.Market size and forecast, by therapeutic area
8.4.6.Market size and forecast, by end user

8.4.6.1.Japan market size and forecast
8.4.6.1.1.Market size and forecast, by cell type
8.4.6.1.2.Market size and forecast, by therapy type
8.4.6.1.3.Market size and forecast, by therapeutic area
8.4.6.1.4.Market size and forecast, by end user

8.4.6.2.India market size and forecast

8.4.6.2.1.Market size and forecast, by cell type
8.4.6.2.2.Market size and forecast, by therapy type
8.4.6.2.3.Market size and forecast, by therapeutic area
8.4.6.2.4.Market size and forecast, by end user

8.4.6.3.China market size and forecast

8.4.6.3.1.Market size and forecast, by cell type
8.4.6.3.2.Market size and forecast, by therapy type
8.4.6.3.3.Market size and forecast, by therapeutic area
8.4.6.3.4.Market size and forecast, by end user

8.4.6.4.Australia market size and forecast

8.4.6.4.1.Market size and forecast, by cell type
8.4.6.4.2.Market size and forecast, by therapy type
8.4.6.4.3.Market size and forecast, by therapeutic area
8.4.6.4.4.Market size and forecast, by end user

8.4.6.5.Rest of Asia-Pacific market size and forecast

8.4.6.5.1.Market size and forecast, by cell type
8.4.6.5.2.Market size and forecast, by therapy type
8.4.6.5.3.Market size and forecast, by therapeutic area
8.4.6.5.4.Market size and forecast, by end user

8.5.LAMEA

8.5.1.Key market trends and opportunities
8.5.2.Market size and forecast
8.5.3.Market size and forecast, by cell type
8.5.4.Market size and forecast, by therapy type
8.5.5.Market size and forecast, by therapeutic area
8.5.6.Market size and forecast, by end user

8.5.6.1.Brazil market size and forecast

8.5.6.1.1.Market size and forecast, by cell type
8.5.6.1.2.Market size and forecast, by therapy type
8.5.6.1.3.Market size and forecast, by therapeutic area
8.5.6.1.4.Market size and forecast, by end user

8.5.6.2.Saudi Arabia market size and forecast

8.5.6.2.1.Market size and forecast, by cell type
8.5.6.2.2.Market size and forecast, by therapy type
8.5.6.2.3.Market size and forecast, by therapeutic area
8.5.6.2.4.Market size and forecast, by end user

8.5.6.3.South Africa market size and forecast

8.5.6.3.1.Market size and forecast, by cell type
8.5.6.3.2.Market size and forecast, by therapy type
8.5.6.3.3.Market size and forecast, by therapeutic area
8.5.6.3.4.Market size and forecast, by end user

8.5.6.4.Rest of LAMEA market size and forecast

8.5.6.4.1.Market size and forecast, by cell type
8.5.6.4.2.Market size and forecast, by therapy type
8.5.6.4.3.Market size and forecast, by therapeutic area
8.5.6.4.4.Market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

9.1.ALLOSOURCE

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments

9.2.CELLS FOR CELLS

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio

9.3.HOLOSTEM TERAPIE AVANZATE SRL

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio

9.4.JCR PHARMACEUTICALS CO., LTD.

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.KOLON TISSUEGENE, INC.

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Key strategic moves and developments

9.6.MEDIPOST CO., LTD.

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance

9.7.MESOBLAST LTD

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance

9.8.NUVASIVE, INC.

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance

9.9.OSIRIS THERAPEUTICS, INC.

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio

9.10.STEMEDICA CELL TECHNOLOGIES, INC.

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio

LIST OF TABLES

TABLE 01.CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 02.CELL THERAPY MARKET FOR STEM CELL, BY REGION, 2019–2027 ($MILLION)
TABLE 03.CELL THERAPY MARKET FOR STEM CELL, BY TYPE, 2019–2027 ($MILLION)
TABLE 04.CELL THERAPY MARKET FOR NON-STEM CELL, BY REGION, 2019–2027 ($MILLION)
TABLE 05.CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 06.CELL THERAPY MARKET FOR AUTOLOGOUS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.CELL THERAPY MARKET FOR ALLOGENEIC, BY REGION, 2019–2027 ($MILLION)
TABLE 08.CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 09.CELL THERAPY MARKET FOR MALIGNANCIES, BY REGION, 2019–2027 ($MILLION)
TABLE 10.CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 11.CELL THERAPY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2019–2027 ($MILLION)
TABLE 12.CELL THERAPY MARKET FOR DERMATOLOGY, BY REGION, 2019–2027 ($MILLION)
TABLE 13.CELL THERAPY MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 15.CELL THERAPY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019–2027 ($MILLION)
TABLE 16.CELL THERAPY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2027 ($MILLION)
TABLE 17.CELL THERAPY MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA CELL THERAPY MARKET, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 21.NORTH AMERICA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 22.NORTH AMERICA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 23.U.S. CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 24.U.S. CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 25.U.S. CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 26.U.S. CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 27.CANADA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 28.CANADA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 29.CANADA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 30.CANADA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 31.MEXICO CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 33.MEXICO CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 34.MEXICO CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 35.EUROPE CELL THERAPY MARKET, 2019–2027 ($MILLION)
TABLE 36.EUROPE CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 37.EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 38.EUROPE CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 39.EUROPE CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 40.UK CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 41.UK CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 42.UK CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 43.UK CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 44.GERMANY CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 45.GERMANY CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 46.GERMANY CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 47.GERMANY CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 48.FRANCE CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 49.FRANCE CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 50.FRANCE CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 51.FRANCE CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 52.SPAIN CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 53.SPAIN CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 54.SPAIN CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 55.SPAIN CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 56.ITALY CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 57.ITALY CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 58.ITALY CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 59.ITALY CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 61.REST OF EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 62.REST OF EUROPE CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 63.REST OF EUROPE CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 64.ASIA-PACIFIC CELL THERAPY MARKET, 2019–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 66.ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 67.ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 68.ASIA-PACIFIC CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 69.JAPAN CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 70.JAPAN CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 71.JAPAN CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 72.JAPAN CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 73.INDIA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 74.INDIA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 75.INDIA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 76.INDIA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 77.CHINA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 78.CHINA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 79.CHINA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 80.CHINA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 82.AUSTRALIA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 83.AUSTRALIA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 84.AUSTRALIA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 86.REST OF ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 88.REST OF ASIA-PACIFIC CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 89.LAMEA CELL THERAPY MARKET, 2019–2027 ($MILLION)
TABLE 90.LAMEA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 91.LAMEA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 92.LAMEA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 93.LAMEA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 94.BRAZIL CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 95.BRAZIL CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 96.BRAZIL CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 97.BRAZIL CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 98.SAUDI ARABIA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 99.SAUDI ARABIA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 102.SOUTH AFRICA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 103.SOUTH AFRICA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 104.SOUTH AFRICA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 105.SOUTH AFRICA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 106.REST OF LAMEA CELL THERAPY MARKET, BY CELL TYPE, 2019–2027 ($MILLION)
TABLE 107.REST OF LAMEA CELL THERAPY MARKET, BY THERAPY TYPE, 2019–2027 ($MILLION)
TABLE 108.REST OF LAMEA CELL THERAPY MARKET, BY THERAPEUTIC AREA, 2019–2027 ($MILLION)
TABLE 109.REST OF LAMEA CELL THERAPY MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 110.ALLOSOURCE: COMPANY SNAPSHOT
TABLE 111.ALLOSOURCE: OPERATING SEGMENTS
TABLE 112.ALLOSOURCE SA: PRODUCT PORTFOLIO
TABLE 113.CELLS FOR CELLS BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 114.CELLS FOR CELLS BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 115.HOLOSTEM: COMPANY SNAPSHOT
TABLE 116.HOLOSTEM: OPERATING SEGMENTS
TABLE 117.HOLOSTEM: PRODUCT PORTFOLIO
TABLE 118.JCR PHARMACEUTICALS.: COMPANY SNAPSHOT
TABLE 119.JCR PHARMACEUTICALS.: PRODUCT PORTFOLIO
TABLE 120.KOLON TISSUEGENE: COMPANY SNAPSHOT
TABLE 121.KOLON TISSUEGENE: PRODUCT SEGMENT
TABLE 122.KOLON TISSUEGENE: PRODUCT PORTFOLIO
TABLE 123.MEDIPOST: COMPANY SNAPSHOT
TABLE 124.MEDIPOST: OPERATING SEGMENTS
TABLE 125.MEDIPOST: PRODUCT PORTFOLIO
TABLE 126.MESOBLAST: COMPANY SNAPSHOT
TABLE 127.MESOBLAST.: PRODUCT PORTFOLIO
TABLE 128.NUVASIVE: COMPANY SNAPSHOT
TABLE 129.NUVASIVE: OPERATING SEGMENTS
TABLE 130.NUVASIVE: PRODUCT PORTFOLIO
TABLE 131.OSIRIS: COMPANY SNAPSHOT
TABLE 132.OSIRIS: PRODUCT PORTFOLIO
TABLE 133.STEMEDICA: COMPANY SNAPSHOT
TABLE 134.STEMEDICA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.CELL THERAPY MARKET SEGMENTATION
FIGURE 02.TOP PLAYER POSITIONING, 2019
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2017–2019*
FIGURE 05.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019* (%)
FIGURE 06.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019*
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.CELL THERAPY MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITIES
FIGURE 13.GLOBAL BONE MARROW MARKET, 2019–2027 ($MILLION)
FIGURE 14.GLOBAL BLOOD MARKET, 2019–2027 ($MILLION)
FIGURE 15.GLOBAL UMBILICAL CORD-DERIVED MARKET, 2019–2027 ($MILLION)
FIGURE 16.GLOBAL ADIPOSE-DERIVED STEM CELL MARKET, 2019–2027 ($MILLION)
FIGURE 17.GLOBAL OTHERS(PLACENTA, AND NONSPECIFIC CELLS) MARKET, 2019–2027 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR AUTOLOGOUS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR ALLOGENIC, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR MALIGNANCIES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR AUTOIMMUNE DISORDER, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR DERMATOLOGY, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR OTHER, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 26.COMPARATIVE ANALYSIS OF CELL THERAPY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 27.U.S. MARKET SIZE AND FORECAST
FIGURE 28.CANADA MARKET SIZE AND FORECAST
FIGURE 29.MEXICO MARKET SIZE AND FORECAST
FIGURE 30.UK MARKET SIZE AND FORECAST
FIGURE 31.GERMANY MARKET SIZE AND FORECAST
FIGURE 32.FRANCE MARKET SIZE AND FORECAST
FIGURE 33.SPAIN MARKET SIZE AND FORECAST
FIGURE 34.ITALY MARKET SIZE AND FORECAST
FIGURE 35.REST OF EUROPE MARKET SIZE AND FORECAST
FIGURE 36.JAPAN MARKET SIZE AND FORECAST
FIGURE 37.INDIA MARKET SIZE AND FORECAST
FIGURE 38.CHINA MARKET SIZE AND FORECAST
FIGURE 39.AUSTRALIA MARKET SIZE AND FORECAST
FIGURE 40.REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST
FIGURE 41.BRAZIL MARKET SIZE AND FORECAST
FIGURE 42.SAUDI ARABIA MARKET SIZE AND FORECAST
FIGURE 43.SOUTH AFRICA MARKET SIZE AND FORECAST
FIGURE 44.REST OF LAMEA MARKET SIZE AND FORECAST
FIGURE 45.JCR PHARMACEUTICALS: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.MEDIPOST: NET SALES, 2017–2019 ($MILLION)
FIGURE 47.MESOBLAST: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.NUVASIVE: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.NUVASIVE: REVENUE SHARE, BY SEGMENT, 2019 (%)

★調査レポート[細胞治療の世界市場2020–2027:機会分析・産業予測] ( Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020–2027 / ALD20NV72) 販売に関する免責事項
[細胞治療の世界市場2020–2027:機会分析・産業予測] ( Cell Therapy Market by Cell Type (Stem Cell and Non-Stem Cell), Therapy Type (Autologous and Allogenic), Therapeutic Area (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, and Others), and End User (Hospitals & Clinics and Academic & Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020–2027 / ALD20NV72) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆